Oral Alternatives to IV Antibiotics

Introduction to Oral Alternatives

The Infectious Diseases Society of America recommends using oral ciprofloxacin 750 mg twice daily or levofloxacin 500-750 mg once daily for gram-negative coverage, and linezolid 600 mg twice daily for systemic MRSA infections 1

For susceptible gram-negative infections, fluoroquinolones such as ciprofloxacin 750 mg orally twice daily provide coverage for Pseudomonas aeruginosa, Enterobacter species, and other Enterobacteriaceae 1, 2
Local fluoroquinolone resistance patterns in Escherichia coli and other Enterobacteriaceae must be reviewed before prescribing, as resistance rates have increased significantly 2

Doxycycline is already highly bioavailable orally and can be continued at 100 mg orally twice daily, maintaining the same spectrum whether given IV or PO, covering MRSA, atypical pathogens, and certain gram-positive organisms 3
For skin and soft tissue infections with suspected or confirmed MRSA, doxycycline 100 mg orally twice daily is an appropriate first-line oral option 3

Linezolid 600 mg orally every 12 hours is the only oral agent with proven efficacy for serious MRSA infections, including bacteremia and pneumonia 1, 3
For less severe MRSA skin/soft tissue infections, sulfamethoxazole-trimethoprim (double-strength) orally twice daily, clindamycin 300-450 mg orally four times daily, or doxycycline 100 mg orally twice daily can be used 3
For C. difficile infection, oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg orally twice daily for 10 days can be used 4, 5, 6

The Infectious Diseases Society of America recommends switching to oral therapy when the patient is afebrile, hemodynamically stable, and able to tolerate oral intake, and source control has been achieved 1
Local antibiograms should be checked before prescribing fluoroquinolones, as E. coli resistance can exceed 30% in some regions 2
Linezolid should be monitored closely if used for more than 14 days due to the risk of bone marrow suppression and irreversible neuropathy 7

For patients with skin and soft tissue infections, the Infectious Diseases Society of America recommends amoxicillin-clavulanate as the first choice 8, 9
For patients with pelvic inflammatory disease, the Centers for Disease Control and Prevention recommends ofloxacin 400 mg orally twice daily for 14 days PLUS metronidazole 500 mg orally twice daily for 14 days 10
For patients with respiratory infections, the Infectious Diseases Society of America recommends levofloxacin 500 mg orally once daily 11
For patients with streptococcal infections, the Infectious Diseases Society of America recommends amoxicillin or clindamycin 8, 11
For patients with staphylococcal infections, the Infectious Diseases Society of America recommends clindamycin or sulfamethoxazole-trimethoprim 8, 9

When selecting an oral regimen, consider the spectrum of coverage needed, with levofloxacin or amoxicillin-clavulanate providing gram-negative coverage, and metronidazole, clindamycin, or amoxicillin-clavulanate providing anaerobic coverage 10

Switch to oral therapy when the patient shows clinical improvement, including defervescence and reduction in symptoms and signs of infection 10
The Centers for Disease Control and Prevention recommends dosing amoxicillin-clavulanate at 875/125 mg orally twice daily 10
The Centers for Disease Control and Prevention recommends continuing doxycycline at 100 mg orally twice daily 10
Schedule follow-up within 72 hours after switching to oral therapy to ensure clinical improvement continues 10